-
A Study of the Donor Screening Experience and the Outcomes from Fecal Transplant in Patients with C. Difficile Infection
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this study is to evaluate clinical experience with donor screening for fecal transplant, and to evaluate the outcomes from fecal transplant and understand risk factors for fecal transplant failure and relapse after fecal transplant.
-
Fecal Microbiota Transplantation For C. Difficile Infection In Solid Organ Transplant Recipients
Rochester, MN
The purpose of this trial is to examine the effect of Fecal Microbiota Transplantation (FMT) compared with Vancomycin for cure of recurrent C. diff infection (CDI) in solid organ transplant (SOT) recipients in a randomized, controlled clinical trial.
-
A Study To Evaluate The Safety And Tolerability Of Rebiotix RBX2660 (Microbiota Suspension) In Subjects With Recurrent Clostridium Difficile Infection
Rochester, MN
To assess the safety and tolerability of RBX2660 in subjects with recurrent CDI who have had prior recurrent CDI that was resolved with antibiotic treatment.
-
Fecal Microbiome Transplant National Registry
Rochester, MN
The overarching goal of the FMT registry is to expand knowledge and optimize practice in the transplantation of fecal microbiota or other gut-related-microbiota products.
-
Mayo Clinic Fecal Microbiota Transplant (FMT) Repository
Rochester, MN
The aim of this protocol is to create a repository for frozen stool samples from donors of Mayo Clinic Rochester MN, FMT program. We will collect a stool aliquot from each 50 grams of donor sample that is processed for FMT at Mayo Clinic Rochester.
-
A Trial of the Effectiveness, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4)
Jacksonville, FL
The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of a single oral administration of study drug CP101 for the prevention of recurrent Clostridioides difficile Infection (CDI) in adult patients.
This Phase 3 trial will be conducted in 2 parts: a randomized, double-blind, placebo-controlled trial arm (Part A) and an optional open-label treatment arm (Part B). After completing standard-of-care (SOC) CDI antibiotics for their most recent CDI recurrence, patients who meet all eligibility requirements will be randomized to receive either the study drug CP101 or placebo in Part A of the trial. Patients will be evaluated for CDI recurrence and safety ...
-
A Study of Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection on Vancomycin Resistant Enterococci Status of Patients
Rochester, MN
The purpose of this study is to evaluate if Vancomycin Resistant Enterococci (VRE) can be eradicated in patients with Clostridium Difficile infection (CDI) through treatment with Fecal Microbiota Transplantation (FMT) when FMT is being done to treat recurrent CDI rather than VRE.